Aside from keeping an eye on shares of Cel-Sci (CVM) this week (see previous blog post), shares of Celsius Holdings (CELH) will be worth watching, too.  Last week we discussed how significant growth in the Celsius distribution network will likely have a very positive impact on earnings over the next couple of quarters and the investing community picked up the indicators, as well, as volume started rolling in and a new 52-week high was set at $5.37.  Not bad, considering shares were trading for under four bucks just a couple of months ago...

Click 'Read More' below to read more...

Read more

Shares of Cel Sci Corp (CVM) closed strong last week, spiking at Friday's close to finish at $7.10, over a buck higher than the lows of near six dollars seen earlier in the week.  As previously discussed, the volatility of CVM this year is based around the pending conclusion of the Phase III Multikine trial, testing its effectiveness in the treatment of head and neck cancer.  Please scroll through my earlier articles on VFC's Stock House for more information on the trial and expected timelines.  You can also visit "Kill CVM Shorts" for a nice collection of DD that builds a case for the long argument of CVM.  In short, tho, the trial has lasted longer than expected, feeding the theory that the longer the trial takes, the more it indicates that Multikine may be working and extending the lives of patients.

While that certainly may be the case...

Click 'Read More' below to read more...

$100 Visa Gift Card (plus $5.95 Purchase Fee)

Read more

If an uptick of trading volume last week is any indication, it might be worth paying some attention to shares of Celsius Holdings (CELH).  For those new to the Celsius story, at one time this company traded as a penny stock on the OTCBB under the symbol CSUH.  One share could be purchased for just three pennies back then, cheaper than a Bazooka Joe.  We are now a far cry from when a two million dollar quarter was a good one.

Once the company's stock received a promotion to the NASDAQ, some massive price gains ensued, before retreating to level off in the three to four dollar range.  Just a few months ago CELH traded for under $3.50, but positive earnings forecasts and news of growing distribution pushed prices higher 

Cick 'Read More' below to read more...


Read more

Shares of CVM closed at $6.36 on Wednesday, 18 July, down nearly three percent on the day and we really can't go a day without discussing this stock.  To follow up on yesterday's  brief synopsis of where we stand with the Cel-Sci story, some after hours trading in the USA and morning trading in the European markets may be worth discussing...  

Give the Gift of Amazon Prime

Read more

Shares of Cel-Sci Corp (CVM) have dropped back to the mid-six dollar range, roughly two bucks lower than where shares traded just days earlier.  As discussed previously, short interest in the stock had been gradually increasing as the share price about quadrupled since early 2019.  I won't re-hash the entire Cel-Sci story here, please see my earlier blog posts for deeper insight.  In short, tho, the company's lead product candidate, Multikine, is in the final stages of a global Phase III trial testing its effect in treating cancer of the head and neck.  Multikine is different from traditional cancer treatments in that it is applied prior to the patient receiving Standard of Care (SoC) treatment, which is key because that is when the body's immune system is strongest; this is a key point, since Multikine harnesses the body's immune system to combat the cancer.  

For investment purposes, the long side of the argument has it that Multikine is working since the trial is still ongoing past previous estimates of completion and since the IDMC recommended the trial continue after a review earlier this year.  Read here for more on the subject.  Two hundred and ninety eight total deaths is the magic number of 'events' that need to occur for the trial to end and according to the most recent company presentation dated this week, that has not yet occurred.  

That could bode well for where CVM is headed...

Click the jump below for more.

Read more